NEA Baptist Clinic - Middlefield is a medicare approved dialysis facility center in Jonesboro, Arkansas and it has 15 dialysis stations. It is located in Craighead county at 3005 Middlefield, Jonesboro, AR, 72401. You can reach out to the office of NEA Baptist Clinic - Middlefield at (870) 934-5705. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. NEA Baptist Clinic - Middlefield has the following ownership type - Non-Profit. It was first certified by medicare in November, 2005. The medicare id for this facility is 042577 and it accepts patients under medicare ESRD program.
| Name | NEA Baptist Clinic - Middlefield |
|---|---|
| Location | 3005 Middlefield, Jonesboro, Arkansas |
| No. of Dialysis Stations | 15 |
| Medicare ID | 042577 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 3005 Middlefield, Jonesboro, Arkansas, 72401 | |
| (870) 934-5705 | |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
| NPI Number | 1447581673 |
| Organization Name | Nea Baptist Clinic Dialysis Center |
| Doing Business As | Northeast Arkansas Clinic Charitable Foundation, Inc. |
| Address | 3005 Middlefield Dr Jonesboro, Arkansas, 72401 |
| Phone Number | (870) 934-5102 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
| NPI Number | 1851352991 |
| Organization Name | Nea Clinic Dialysis Center |
| Doing Business As | Northeast Arkansas Clinic, P.a. |
| Address | 3005 Middlefield Dr Jonesboro, Arkansas, 72401 |
| Phone Number | (870) 934-5705 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 30 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 37 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 41 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 346 |
| Percentage of adult patients getting regular hemodialysis at the center | 90 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at NEA Baptist Clinic - Middlefield with elevated calcium levels.
| Patients with hypercalcemia | 48 |
| Hypercalcemia patient months | 407 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 49 |
| Patients with Serumphosphor less than 3.5 mg/dL | 5 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 19 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 20 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 30 |
| Patients with Serumphosphor greater than 7 mg/dL | 26 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 45 |
| Patient months included in arterial venous fistula and catheter summaries | 341 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 65 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 27 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 52 |
| Hospitalization Rate in facility | 272.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 443.3 |
| Hospitalization Rate: Lower Confidence Limit | 173.6 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at NEA Baptist Clinic - Middlefield were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 32.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 45.8 |
| Readmission Rate: Lower Confidence Limit | 21 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at NEA Baptist Clinic - Middlefield get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .43 (As Expected) |
| SIR: Upper Confidence Limit | 1.43 |
| SIR: Lower Confidence Limit | .07 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether NEA Baptist Clinic - Middlefield's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 35 |
| Transfusion Rate in facility | 76.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 235 |
| Transfusion Rate: Lower Confidence Limit | 28.9 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at NEA Baptist Clinic - Middlefield lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 228 |
| Mortality Rate in facility | 20.6 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 28.3 |
| Mortality Rate: Lower Confidence Limit | 14.5 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago
St Bernards Regional Med Ctr-Dialysis Location: 540 E Washington, Jonesboro, Arkansas, 72401 Phone: (870) 207-4477 |
NEA Baptist Clinic - Middlefield Location: 3005 Middlefield, Jonesboro, Arkansas, 72401 Phone: (870) 934-5705 |
NEA Baptist Clinic - Hilltop Location: 4909 E Johnson Ave, Jonesboro, Arkansas, 72401 Phone: (870) 336-3372 |
News Archive
Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.
TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.
Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.
Even as Republican lawmakers took a hard line during the weekend talk shows, Democrats still maintain the measure will, in the end, be a political advantage.
Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.
› Verified 8 days ago